
TY  - JOUR
AU  - Gulati, Abhishek
AU  - Gerk, Phillip M.
TI  - Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancy
JO  - Journal of Pharmaceutical Sciences
JA  - J. Pharm. Sci.
VL  - 98
IS  - 7
SN  - 0022-3549
UR  - https://doi.org/10.1002/jps.21623
DO  - doi:10.1002/jps.21623
SP  - 2317
EP  - 2335
KW  - ABC transporters
KW  - P-glycoprotein
KW  - multidrug resistance-associated proteins
KW  - placenta
KW  - pregnancy
KW  - transporters
KW  - active transport
KW  - efflux pumps
KW  - pharmacokinetics/pharmacodynamics
KW  - multidrug resistance transporters
PY  - 2009
AB  - Abstract Highly active anti-retroviral therapy (HAART) is used to treat HIV-infected patients and involves administration of multiple antiretroviral drugs acting at different steps of the HIV life cycle. In treating HIV-infected pregnant patients, the aim of therapy is not only to treat the mother but also to prevent the transmission of the virus to the fetus. Among the antiretroviral drugs used, there are differences in the extent of transfer of these drugs across the placenta; HIV protease inhibitors are particularly poorly transferred. Activities of ABC transporters expressed in the human placenta as well as differences in plasma protein binding may account for the poor transplacental transfer of certain drugs. This review discusses factors affecting the extent of placental transfer of antiretroviral drugs during pregnancy. These issues may also apply to drugs in other therapeutic categories. ? 2008 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 98:2317?2335, 2009
ER  - 

AU  - Habing, Amy M.
AU  - Byron, Julie K.
C7  - pp. 261-288
TI  - Imaging of the Urinary Tract
SN  - 9781118378281
UR  - https://doi.org/10.1002/9781118910924.ch26
DO  - doi:10.1002/9781118910924.ch26
SP  - 261-288
KW  - cats
KW  - computed tomography (CT)
KW  - cystography
KW  - dogs
KW  - excretory urography (EU)
KW  - urinary tract
PY  - 2009
AB  - Summary Imaging, plain and contrast-enhanced, and uroendoscopy is essential to interventional evaluation and treatment of the urinary tract of dog and cat, and are often best used in combination. This chapter explains the indications, procedures, complications, and interpretation of some of the most common imaging studies performed for the urinary tract. Excretory urography (EU) may be performed using traditional radiography, fluoroscopy, or computed tomography (CT). Contraindications of these techniques are related to the use of intravenous injection of iodinated contrast media and the need for sedation or general anesthesia. There are three phases of the excretory urogram: vascular, nephrogram, and pyelogram. Contrast cystography allows for visualization of the urinary bladder, assessment of bladder wall integrity, thickness and contour, and the investigation of intraluminal abnormalities such as cystoliths and masses. The urinary bladder should be evaluated for normal margination, shape, location, and lack of contrast media extravasation.
ER  - 

TY  - JOUR
TI  - Original Clinical Research
JO  - Oral Diseases
JA  - Oral Dis
VL  - 20
IS  - s2
SN  - 9781118378281
UR  - https://doi.org/10.1111/odi.12277_1
DO  - doi:10.1111/odi.12277_1
SP  - 7
EP  - 24
PY  - 2014
ER  - 

TY  - JOUR
TI  - Poster
JO  - Transplant International
JA  - Transpl Int
VL  - 26
IS  - s1
SN  - 9781118378281
UR  - https://doi.org/10.1111/tri.12181
DO  - doi:10.1111/tri.12181
SP  - 28
EP  - 57
PY  - 2013
ER  - 

AU  - Falsey, Ann R.
C7  - pp. 1723-1737
TI  - Infectious Diseases
SN  - 9780470090558
UR  - https://doi.org/10.1002/047009057X.ch145
DO  - doi:10.1002/047009057X.ch145
SP  - 1723-1737
KW  - fever
KW  - infection
KW  - influenza
KW  - vaccination
PY  - 2013
AB  - Summary This chapter contains sections titled: Introduction Epidemiology of Infections Clinical Presentation Fever of Unknown Origin Infection Control in Long-Term Care Facilities Specific Infections Vaccination Key References References
ER  - 

TY  - JOUR
TI  - FOCUSED WORKSHOPS
JO  - European Journal of Neurology
VL  - 14
IS  - s1
SN  - 9780470090558
UR  - https://doi.org/10.1111/j.1468-1331.2007.01937.x
DO  - doi:10.1111/j.1468-1331.2007.01937.x
SP  - 302
EP  - 311
PY  - 2007
ER  - 

TY  - JOUR
AU  - Iezzoni, Lisa I.
TI  - Multiple Chronic Conditions and Disabilities: Implications for Health Services Research and Data Demands
JO  - Health Services Research
VL  - 45
IS  - 5p2
SN  - 9780470090558
UR  - https://doi.org/10.1111/j.1475-6773.2010.01145.x
DO  - doi:10.1111/j.1475-6773.2010.01145.x
SP  - 1523
EP  - 1540
KW  - Chronic conditions
KW  - disability
KW  - functional status
KW  - comparative effectiveness research
KW  - quality measurement
KW  - health information technology
KW  - coding nomenclatures
PY  - 2010
AB  - Increasing numbers of Americans are living with multiple chronic conditions (MCCs) and disabilities. Addressing health care needs of persons with MCCs or disabilities presents challenges on many levels. For health services researchers, priorities include (1) considering MCCs and disabilities in comparative effectiveness research (CER) and assessing quality of care; and (2) identifying and evaluating the data needed to conduct CER, performance measure development, and other research to inform health policy and public health decisions concerning persons with MCCs or disabilities. Little information is available to guide CER or treatment choices for persons with MCCs or disabilities, however, because they are typically excluded from clinical trials that produce the scientific evidence base. Furthermore, most research funding flows through public and private agencies oriented around single organ systems or diseases. Likely changes in the data landscape?notably wider dissemination of electronic health records (EHRs) and moving toward updated coding nomenclatures?may increase the information available to monitor health care service delivery and quality for persons with MCCs and disabilities. Generating this information will require new methods to extract and code information about MCCs and functional status from EHRs, especially narrative texts, and incorporating coding nomenclatures that capture critical dimensions of functional status and disability.
ER  - 

TY  - JOUR
TI  - Abstracts—Posters
JO  - Alcoholism: Clinical and Experimental Research
JA  - Alcohol Clin Exp Res
VL  - 40
IS  - S1
SN  - 9780470090558
UR  - https://doi.org/10.1111/acer.13084
DO  - doi:10.1111/acer.13084
SP  - 16A
EP  - 247A
PY  - 2016
ER  - 

TY  - JOUR
TI  - ORAL PRESENTATION
JO  - Respirology
JA  - Respirology
VL  - 21
IS  - S3
SN  - 9780470090558
UR  - https://doi.org/10.1111/resp.12939_14
DO  - doi:10.1111/resp.12939_14
SP  - 20
EP  - 79
PY  - 2016
ER  - 

TY  - JOUR
TI  - Poster Tours
JO  - Pediatric Diabetes
JA  - Pediatr Diabetes
VL  - 14
IS  - s18
SN  - 9780470090558
UR  - https://doi.org/10.1111/pedi.12075
DO  - doi:10.1111/pedi.12075
SP  - 50
EP  - 154
PY  - 2013
ER  - 

TY  - JOUR
AU  - Tortelli, R.
AU  - Ruggieri, M.
AU  - Cortese, R.
AU  - D'Errico, E.
AU  - Capozzo, R.
AU  - Leo, A.
AU  - Mastrapasqua, M.
AU  - Zoccolella, S.
AU  - Leante, R.
AU  - Livrea, P.
AU  - Logroscino, G.
AU  - Simone, I. L.
TI  - Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression
JO  - European Journal of Neurology
JA  - Eur J Neurol
VL  - 19
IS  - 12
SN  - 9780470090558
UR  - https://doi.org/10.1111/j.1468-1331.2012.03777.x
DO  - doi:10.1111/j.1468-1331.2012.03777.x
SP  - 1561
EP  - 1567
KW  - amyotrophic lateral sclerosis
KW  - biomarkers
KW  - cerebrospinal fluid
KW  - neurofilament light chain
KW  - prognosis
PY  - 2012
AB  - Background To date there are no biomarkers with proven reliability as a measure of disease burden in amyotrophic lateral sclerosis (ALS). The aim of our study is to assess the neurofilament light chain (NFL) in cerebrospinal fluid (CSF) samples as a measure of disease activity and progression in ALS. Methods Thirty-seven consecutive patients with ALS, 25 with chronic inflammatory demyelinating polyneuropathy and 21 with other neurodegenerative diseases were evaluated. CSF NFL levels were assayed by two-site solid-phase sandwich ELISA. In patients with ALS, neurological status was assessed by the revised ALS Functional Rating Scale (ALSFRS-r) and the Medical Research Council scale, and the progression of the disease was evaluated using the ?diagnostic delay? and the ?progression rate?. Results Cerebrospinal fluid NFL levels were higher in ALS cases than in controls (P < 0.0001). Using receiver operating curve analysis, an optimal NFL cut-off of 1981 ng/l discriminated between patients with ALS and neurological controls, with a sensitivity of 78.4% and specificity of 72.5%. Multivariate logistic regression confirmed the association between CSF NFL levels and the presence of ALS (age and sex adjusted odds ratio for ALS 8.9; 95% CI 3.1?25.8; P < 0.0001). In ALS, CSF NFL negatively correlated with the diagnostic delay (P < 0.0001) and the ALSFRS-r (P = 0.014) and positively with the progression rate (P < 0.0001). Conclusions High CSF NFL levels were found in patients with ALS, reflecting the burden of neurodegeneration. The significant relation between CSF NFL levels and disease progression suggests that NFL may be a useful marker of disease activity and progression in ALS.
ER  - 

TY  - JOUR
TI  - Poster Session 2, Monday 10 September
JO  - European Journal of Neurology
VL  - 19
IS  - s1
SN  - 9780470090558
UR  - https://doi.org/10.1111/j.1468-1331.2012.03889.x
DO  - doi:10.1111/j.1468-1331.2012.03889.x
SP  - 458
EP  - 807
PY  - 2012
ER  - 

TY  - JOUR
TI  - Posters
JO  - Bipolar Disorders
JA  - Bipolar Disord
VL  - 17
IS  - S1
SN  - 9780470090558
UR  - https://doi.org/10.1111/bdi.12309
DO  - doi:10.1111/bdi.12309
SP  - 58
EP  - 142
PY  - 2015
ER  - 

C7  - pp. 581-594
TI  - Index
SN  - 9781405163217
UR  - https://doi.org/10.1002/9781444319583.index
DO  - doi:10.1002/9781444319583.index
SP  - 581-594
PY  - 2015
ER  - 

TY  - JOUR
TI  - Abstracts–Posters
JO  - Alcoholism: Clinical and Experimental Research
JA  - Alcohol Clin Exp Res
VL  - 37
IS  - s2
SN  - 9781405163217
UR  - https://doi.org/10.1111/acer.12162
DO  - doi:10.1111/acer.12162
SP  - 11A
EP  - 253A
PY  - 2013
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - HPB
VL  - 13
IS  - s1
SN  - 9781405163217
UR  - https://doi.org/10.1111/j.1477-2574.2011.00291.x
DO  - doi:10.1111/j.1477-2574.2011.00291.x
SP  - 1
EP  - 77
PY  - 2011
ER  - 

TY  - JOUR
TI  - International symposium on cell biology: from basic research to clinical applications
JO  - Cell Biology International
VL  - 28
IS  - 8‐9
SN  - 9781405163217
UR  - https://doi.org/10.1016/j.cellbi.2004.07.001
DO  - doi:10.1016/j.cellbi.2004.07.001
SP  - S1
EP  - S30
PY  - 2004
ER  - 

TY  - JOUR
TI  - ADRF Research Grant Abstracts
JO  - Australian Dental Journal
VL  - 51
IS  - 4
SN  - 9781405163217
UR  - https://doi.org/10.1111/j.1834-7819.2006.tb00444.x
DO  - doi:10.1111/j.1834-7819.2006.tb00444.x
SP  - S3
EP  - S35
PY  - 2006
ER  - 

TY  - JOUR
TI  - Oral Presentations
JO  - Mycoses
JA  - Mycoses
VL  - 58
IS  - S3
SN  - 9781405163217
UR  - https://doi.org/10.1111/myc.12361
DO  - doi:10.1111/myc.12361
SP  - 2
EP  - 39
PY  - 2015
ER  - 

TY  - JOUR
TI  - Oral Abstract Sessions
JO  - Allergy
JA  - Allergy
VL  - 68
IS  - s97
SN  - 9781405163217
UR  - https://doi.org/10.1111/all.12247
DO  - doi:10.1111/all.12247
SP  - 1
EP  - 104
PY  - 2013
ER  - 
